The previous findings prompted us to investigate whether K-ras oncogenic signaling increases ROS levels through the activation of NOX and whether modulators of NOX could provide a potential therapeutic opportunity for pancreatic cancer through a redox-mediated mechanism. This evidence concerns the gene KRAS and familial pancreatic carcinoma.